Axial reports findings of elevated 4-EPS in children with ASD

May 09, 2018

BOSTON and Pasadena, Calif., May 9, 2018 - Axial Biotherapeutics, a biotechnology company building a unique class of microbial-inspired therapeutics for neurological diseases, today announced that Srinivas Rao, M.D., Ph.D., Axial's Chief Medical Officer, will present new data from Axial's research of the link between the human gut microbiome and Autism Spectrum Disorder (ASD) at the International Society for Autism Research (INSAR) conference held May 09 - 12, 2018 in de Doelen ICC Rotterdam, Netherlands. The findings showed that concentrations of the bacterial metabolite, 4-ethylphenylsulfate (4-EPS) were elevated as much as six-fold in serum samples from children with ASD compared to healthy controls in replicate analyses.

This research builds on previous work published by Axial's Co-founder and Caltech Professor, Sarkis Mazmanian, Ph.D., that demonstrated causality between 4-EPS and anxiety-like behaviors in the "maternal immune activation" (MIA) mouse model of ASD. The MIA model recapitulates key features of the autism phenotype, including increased anxiety, stereotypic behaviors, and decreased vocalizations and social behaviors. Dr. Mazmanian found changes in the gut microbiome (dysbiosis), increased intestinal permeability (IP), and elevated levels of the putative bacterial metabolite 4-EPS in MIA mice, compared to controls. Oral treatment with B. fragilis, a human commensal gut bacterial species, resulted in restoration of gut microbial profiles, decreased IP, and markedly reduced serum concentrations of 4-EPS.

The current study aimed to evaluate 4-EPS levels in children with ASD compared to samples from control children. Two analyses were performed, a 4-EPS targeted analysis in 103 pediatric subjects and a non-targeted serum metabolomics study involving 230 children (cohorts from the "Childhood Autism Risks from Genetics and the Environment" study ongoing at the Univ. of California Davis). 4-EPS concentrations were found to be significantly elevated in children with ASD vs. healthy controls in both analyses. In addition, elevated levels were associated with worse social performance on two separate measurements. The impact of this elevation on behavior, and the impact of treatment with B. fragilis and with Axial's small molecule therapeutic, AB-2004, will be the subject of subsequent human clinical studies.

"Our clinical biomarker results, derived from one of the largest ASD serum metabolomics studies conducted to date, are encouraging," said David H. Donabedian, Ph.D., Co-founder & CEO of Axial Biotherapeutics. "These data, which are the first we have presented from our ASD program, present a major advancement in our mission to develop microbiome inspired therapeutics as a potential new approach to treating neurological diseases and disorders like ASD."

Poster Presentation Details:

Title: Elevation of a Putative Bacterial Metabolite in a Pediatric ASD Population
Abstract No: 28205
Date/Time: Friday, May 11, 2018 / 5:30 PM-7:00 PM
Location: Hall Grote Zaal (de Doelen ICC Rotterdam)
-end-
About Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. http://www.axialbiotherapeutics.com

Contacts

MacDougall Biomedical Communications
Kari Watson or Shai Biran, Ph.D.
Direct: +1-781-235-3060
kwatson@macbiocom.com or sbiran@macbiocom.com

MacDougall Biomedical Communications, Inc.

Related Autism Spectrum Disorder Articles from Brightsurf:

New genes related to autism spectrum disorder
The lack of some genes in the BEC/TCEAL cluster could be related to some alterations associated with the autism spectrum disorder, according to a preclinical study published in the journal Genome Biology, and led by Professor Jordi Garcia Fernàndez, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB), and researcher Jaime Carvajal, from the Andalusian Centre for Developmental Biology - University Pablo de Olavide (CSIC-UPO).

FABP4: Preschool-aged biomarker discovered for autism spectrum disorder
Researchers at the RIKEN Center for Brain Science in Japan have discovered a biomarker that can detect autism spectrum disorder (ASD) in preschool-aged children.

Autism spectrum disorder can be predicted from health checkups at 18 months
An early diagnosis of autism spectrum disorder, a type of developmental disorder was found to be effective from routine health checkups of infants at 18 months of age.

Alteration of calcium channel signaling may explain mechanism of autism spectrum disorder
Based on altering calcium channel kinetics and gene activation exhibited by the Timothy mutant, these results provide insight into the cellular mechanism that allows predicting disease risk, and genetic diagnosis of individuals with neurodevelopmental disorders.

Scientists uncover new genetic mutations linked to autism spectrum disorder
Scientists at Sanford Burnham Prebys Medical Discovery Institute and Radboud University Medical Center in the Netherlands have identified mutations in a gene called CNOT1 that affect brain development and impair memory and learning.

Unique metabolic markers detect over 50% of children affected by autism spectrum disorder
Blood sample analyses from the Children's Autism Metabolome Project have now reproducibly identified unique metabolic signatures in over 50% of the participating children with autism.

Genetic rescue of SHANK3 is potential therapy in rare forms of autism spectrum disorder
A mouse study by Craig Powell, M.D., Ph.D., and colleagues suggests that early genetic rescue may be a potential therapy in autism spectrum disorder, or ASD.

Investigation of inherited mutations in Autism Spectrum Disorder
Scientists from the Institute for Stem Cell Science and Regenerative Medicine (inStem) and collaborators investigated inherited mutations in Autism Spectrum Disorder.

Using virtual reality to help individuals with autism spectrum disorder
Novel interventions using virtual reality to aid individuals with autism spectrum disorder (ASD) handle common scenarios may include helping youngsters navigate air travel.

Studies of autism spectrum disorder reveal new avenues of neuroscience research
Advances in the study of cognitive disorders, including Autism Spectrum Disorder (ASD), may pave the way for future treatments.

Read More: Autism Spectrum Disorder News and Autism Spectrum Disorder Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.